In non-small cell lung cancer (NSCLC), tumour-derived ANXA2 activates Toll-like receptor 2 (TLR2) receptors and downstream signalling on tumour-associated neutrophils (TANs), subsequently promoting ARG1 expression [132]. Here, TLR2 is linked to non-small cell lung carcinoma.